checkAd
    Startseite > Aktien > Jaguar Health > Nachrichten
    Jaguar Health Aktie
    0,8032
     
    EUR
    -2,64 %
    -0,0218 EUR
    Letzter Kurs 08.09.21 Tradegate
    0,7946
     
    EUR
    5.034 STK
    Geldkurs 08.09.21
    0,8282
     
    EUR
    4.829 STK
    Briefkurs 08.09.21
    ISIN: US47010C4096 · WKN: A2PLYX · USA

    Neueste Nachrichten

    Jaguar Health Reports First Quarter 2024 Financial Results
    14.05.24 · Accesswire · Jaguar Health
    REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
    13.05.24 · Accesswire · Jaguar Health
    Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
    09.05.24 · Accesswire · Jaguar Health
    Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
    08.05.24 · Accesswire · Jaguar Health
    Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
    06.05.24 · Accesswire · Jaguar Health
    Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
    29.04.24 · Accesswire · Jaguar Health
    Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
    22.04.24 · Accesswire · Jaguar Health
    Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
    18.04.24 · Accesswire · Jaguar Health
    Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
    16.04.24 · Accesswire · Jaguar Health
    Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
    09.04.24 · Accesswire · Jaguar Health
    Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
    08.04.24 · Accesswire · Jaguar Health
    Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
    02.04.24 · Accesswire · Jaguar Health